The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Open accessAbstract
Irinotecan (CPT-11) is a promising antitumor agent, recently approved for use in patients with metastatic colorectal cancer. Its active metabolite, SN-38, is glucuronidated by hepatic uridine diphosphate glucuronosyltransferases (UGTs). The major dose-limiting toxicity of irinotecan therapy is diarrhea, which is believed to be secondary to the biliary excretion of SN-38, the extent of which is determined by SN-38 glucuronidation. The purpose of this study was to identify the specific isoform of UGT involved in SN-38 glucuronidation. In vitro glucuronidation of SN-38 was screened in hepatic microsomes from normal rats (n = 4), normal humans (n = 25), Gunn rats (n = 3), and patients (n = 4) with Crigler-Najjar type I (CN-I) syndrome. A wide intersubject variability in in vitro SN-38 glucuronide formation rates was found in humans. Gunn rats and CN-I patients lacked SN-38 glucuronidating activity, indicating the role of UGT1 isoform in SN-38 glucuronidation. A significant correlation was observed between SN-38 and bilirubin glucuronidation (r = 0.89; P = 0.001), whereas there was a poor relationship between para-nitrophenol and SN-38 glucuronidation (r = 0.08; P = 0.703). Intact SN-38 glucuronidation was observed only in HK293 cells transfected with the UGT1A1 isozyme. These results demonstrate that UGT1A1 is the isoform responsible for SN-38 glucuronidation. These findings indicate a genetic predisposition to the metabolism of irinotecan, suggesting that patients with low UGT1A1 activity, such as those with Gilbert's syndrome, may be at an increased risk for irinotecan toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Elferink, R. P. J. O., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331802 · Cited by 1,447
Chen, C. A., & Okayama, H. (1988) · PubMed · Cited by 894
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
Monaghan, G., Ryan, M., Hume, R., Burchell, B., & Seddon, R. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91273-8 · Cited by 585
CONGENITAL FAMILIAL NONHEMOLYTIC JAUNDICE WITH KERNICTERUS
Crigler, J. F., & Najjar, V. A. (1952) · PEDIATRICS · doi:10.1542/peds.10.2.169 · Cited by 548
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
Self-citationBosma, P. J., Seppen, J., Goldhoorn, B., Bakker, C., Oude Elferink, R. P., Chowdhury, J. R., Chowdhury, N. R., & Jansen, P. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32403-1 · Cited by 446
Human UGT2B7 catalyzes morphine glucuronidation.
Coffman, B. L., Rios, G. R., King, C. D., et al. (1997) · PubMed · Cited by 426
Self-citationKunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., YOKOKURA, T., Sawada, S., Miyasaka, T., & Mutai, M. (1987) · PubMed · Cited by 410
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1128 · Cited by 352
Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
KANEDA, N., Nagata, H., Furuta, T., & YOKOKURA, T. (1990) · PubMed · Cited by 291
BURCHELL, B., NEBERT, D. W., NELSON, D. R., BOCK, K. W., IYANAGI, T., JANSEN, P. L. M., LANCET, D., MULDER, G. J., CHOWDHURY, J. R., SIEST, G., et al. (1991) · DNA and Cell Biology · doi:10.1089/dna.1991.10.487 · Cited by 276
Self-citationRitter, J. K., Crawford, J. M., & Owens, I. S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35280-8 · Cited by 256
Jin, C., Miners, J. O., Lillywhite, K. J., & Mackenzie, P. I. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10294-2 · Cited by 226
Specificity of human UDP-Glucuronosyltransferases and xenobiotic glucuronidation
Burchell, B., Brierley, C. H., & Rance, D. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02073-r · Cited by 224
Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., & Ratain, M. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1502 · Cited by 182
Self-citationHaaz, M., Rivory, L. P., Riché, C., Vernillet, L., & Robert, J. (1998) · PubMed · Cited by 172
King, C. D., Green, M. D., Rios, G. R., Coffman, B. L., Owens, I. S., Bishop, W. P., & Tephly, T. R. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0320 · Cited by 169
Self-citationHarding, D., Fournel-Gigleux, S., Jackson, M. R., & Burchell, B. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.22.8381 · Cited by 165
Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M.-C., Mathieu-Boué, A., & Houghton, J. A. (1993) · PubMed · Cited by 161
Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome
De Morais, S. M. F., Uetrecht, J. P., & Wells, P. G. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90106-9 · Cited by 160
Green, M. D., Oturu, E. M., & Tephly, T. R. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07570-1 · Cited by 156
Self-citationAraki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., & Hoshi, A. (1993) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1993.tb02031.x · Cited by 142
Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides.
Green, M. D., Bishop, W. P., & Tephly, T. R. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06536-5 · Cited by 124
Self-citationThe Uridine Diphosphate Glucuronosyltransferase Multigene Family: Function and Regulation
Clarke, D. J., & Burchell, B. (1994) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-78429-3_1 · Cited by 114
Bosma, P. J., Chowdhury, J. R., Huang, T., Lahiri, P., Elferink, R. P. J. O., van Es, H. H. G., Lederstein, M., Whitington, P. F., Jansen, P. L. M., & Chowdhury, N. R. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.10.1634050 · Cited by 112
Self-citationPurba, H., Maggs, J. L., Orme, M., Back, D., & Park, B. K. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03074.x · Cited by 106
Vassal, G., Terrier-Lacombe, M.-J., Bissery, M.-C., Vénuat, A. M., Gyergyay, F., Bénard, J., Morizet, J., Boland, I., Ardouin, P., Paillerets, B. B., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.398 · Cited by 102
Atsumi, R., Suzuki, W., & Hakusui, H. (1991) · Xenobiotica · doi:10.3109/00498259109039556 · Cited by 101
Gupta, E., Wang, X., Ramı́rez, J., & Ratain, M. J. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050595 · Cited by 95
Self-citationComparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds.
King, C. D., Rios, G. R., Green, M. D., Mackenzie, P. I., & Tephly, T. R. (1997) · PubMed · Cited by 63
Self-citationSim, S. M., Back, D., & Breckenridge, A. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05607.x · Cited by 63
Alteration of drug metabolism in Gilbert's syndrome.
Carulli, N., de Leòn, M. P., Mauro, E., Manenti, F., & Ferrari, A. (1976) · Gut · doi:10.1136/gut.17.8.581 · Cited by 54
Endogenous Substrates for Udp-Glucuronosyl-Transferases
Tephly, T. R., Green, M. D., Puig, J., & Irshaid, Y. M. (1988) · Xenobiotica · doi:10.3109/00498258809042244 · Cited by 48
Self-citationTakasuna, K., KASAI, Y., Kitano, Y., Mori, K., KAKIHATA, K., Hirohashi, M., & Nomura, M. (1995) · Folia Pharmacologica Japonica · doi:10.1254/fpj.105.447 · Cited by 35
Battaglia, E., Senay, C., Fournel‐Gigleux, S., Herber, R., Siest, G., & Magdalou, J. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00453-6 · Cited by 32
Cited by
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Self-citationDelivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Self-citationAlmazroo, O. A., Miah, M. K., & Venkataramanan, R. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.08.001 · Cited by 681
Wang, L., McLeod, H. L., & Weinshilboum, R. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1010600 · Cited by 613
Metadata
- Authors
- Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-15
- Volume
- 101
- Issue
- 4
- Pages
- 847-854
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2021622287
- Cited by
- 686
- References
- 37
- FWCI
- 20.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.